Literature DB >> 19406912

Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation.

Sandra B Haudek1, Damon Gupta, Oliver Dewald, Robert J Schwartz, Lei Wei, JoAnn Trial, Mark L Entman.   

Abstract

AIMS: Highly proliferative, CD34+/CD45+ fibroblasts derived from monocytic, blood-borne precursor cells play a critical role in the development of fibrosis in a murine ischaemic/reperfusion cardiomyopathy (I/RC) model. The differentiation of human monocytes into fibroblasts in vitro occurs after transendothelial migration (TEM) induced by monocyte chemoattractant protein 1 (MCP-1). Because Rho-associated kinase-1 (ROCK-1) has been implicated in fibrosis and leukocyte TEM, we investigated its involvement in I/RC. METHODS AND
RESULTS: We subjected mice with genetic deletion of ROCK-1 to I/RC. We found that ROCK-1(-/-) mice did not develop the fibrosis and cardiac dysfunction characteristic for I/RC: compared with wild-type, ROCK-1(-/-) hearts showed markedly lower numbers of I/RC-induced alpha-smooth muscle actin+ fibroblasts and CD34+/CD45+ fibroblast precursors. Isolated cardiac fibroblasts from ROCK-1(-/-) mice undergoing I/RC were large and slowly proliferating, similar to fibroblasts isolated from sham-treated hearts. We also performed in vitro assays in which human peripheral blood mononuclear cells (PBMC) migrated through endothelial cells in response to MCP-1. Prior to migration, PBMC were incubated with ROCK-1-targeting small interfering RNA to silence ROCK-1 expression. We found that an 80% reduction of ROCK-1 protein did not inhibit TEM, but significantly reduced the amount of mononuclear cells that differentiated into fibroblasts by >20-fold.
CONCLUSION: Our data implicate an important role for ROCK-1 in the differentiation, but not in the TEM of monocytes that mature into cardiac fibroblasts. These cells mediate non-adaptive fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406912      PMCID: PMC2709463          DOI: 10.1093/cvr/cvp135

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  34 in total

Review 1.  Regulation and functions of Rho-associated kinase.

Authors:  M Amano; Y Fukata; K Kaibuchi
Journal:  Exp Cell Res       Date:  2000-11-25       Impact factor: 3.905

Review 2.  Rocks: multifunctional kinases in cell behaviour.

Authors:  Kirsi Riento; Anne J Ridley
Journal:  Nat Rev Mol Cell Biol       Date:  2003-06       Impact factor: 94.444

3.  Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure.

Authors:  Shinji Satoh; Yasuko Ueda; Masamichi Koyanagi; Toshiaki Kadokami; Masahiro Sugano; Yasuji Yoshikawa; Naoki Makino
Journal:  J Mol Cell Cardiol       Date:  2003-01       Impact factor: 5.000

4.  Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species.

Authors:  Oliver Dewald; Nikolaos G Frangogiannis; Martin Zoerlein; Georg D Duerr; Christina Klemm; Pascal Knuefermann; George Taffet; Lloyd H Michael; James D Crapo; Armin Welz; Mark L Entman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-13       Impact factor: 11.205

5.  Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death.

Authors:  Dean Thumkeo; Jeongsin Keel; Toshimasa Ishizaki; Masaya Hirose; Kimiko Nonomura; Hiroko Oshima; Masanobu Oshima; Makoto M Taketo; Shuh Narumiya
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

6.  Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system.

Authors:  Midoriko Higashi; Hiroaki Shimokawa; Tsuyoshi Hattori; Junko Hiroki; Yasushi Mukai; Keiko Morikawa; Toshihiro Ichiki; Shosuke Takahashi; Akira Takeshita
Journal:  Circ Res       Date:  2003-09-18       Impact factor: 17.367

Review 7.  The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis.

Authors:  Toshiki Moriyama; Katsuyuki Nagatoya
Journal:  Drug News Perspect       Date:  2004 Jan-Feb

8.  Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury.

Authors:  Weike Bao; Erding Hu; Ling Tao; Rogely Boyce; Rosanna Mirabile; Douglas T Thudium; Xin-ling Ma; Robert N Willette; Tian-li Yue
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

9.  Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice.

Authors:  Hong-Wei Wang; Ping-Yen Liu; Naotsugu Oyama; Yoshiyuki Rikitake; Shiro Kitamoto; Jonathan Gitlin; James K Liao; William A Boisvert
Journal:  FASEB J       Date:  2008-06-12       Impact factor: 5.191

10.  Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice.

Authors:  Ziad Mallat; Andrea Gojova; Vincent Sauzeau; Valérie Brun; Jean-Sébastien Silvestre; Bruno Esposito; Régine Merval; Hervé Groux; Gervaise Loirand; Alain Tedgui
Journal:  Circ Res       Date:  2003-10-02       Impact factor: 17.367

View more
  56 in total

Review 1.  Electrical and mechanical stimulation of cardiac cells and tissue constructs.

Authors:  Whitney L Stoppel; David L Kaplan; Lauren D Black
Journal:  Adv Drug Deliv Rev       Date:  2015-07-30       Impact factor: 15.470

2.  Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Authors:  Yavuz Pehlivan; Servet Yolbas; Gozde Yıldırım Cetin; Fatma Alibaz-Oner; Yonca Cagatay; Neslihan Yilmaz; Serdar Oztuzcu; Salim Donmez; Metin Ozgen; Suleyman Serdar Koca; Omer Nuri Pamuk; Mehmet Sayarlıoglu; Bunyamin Kisacik; Haner Direskeneli; Abdullah Tuncay Demiryurek; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2015-11-28       Impact factor: 2.631

3.  Mechanism of fibrotic cardiomyopathy in mice expressing truncated Rho-associated coiled-coil protein kinase 1.

Authors:  Xiangsheng Yang; Qi Li; Xi Lin; Yanlin Ma; Xiaojing Yue; Zhenyin Tao; Fen Wang; Wallace L Mckeehan; Lei Wei; Robert J Schwartz; Jiang Chang
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

4.  SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.

Authors:  Yvette Langdon; Panna Tandon; Erika Paden; Jennifer Duddy; Joan M Taylor; Frank L Conlon
Journal:  Development       Date:  2012-01-25       Impact factor: 6.868

5.  Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart.

Authors:  Katarzyna A Cieslik; George E Taffet; Signe Carlson; Jesus Hermosillo; Joann Trial; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2010-10-23       Impact factor: 5.000

Review 6.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 7.  Cell type-specific signaling function of RhoA GTPase: lessons from mouse gene targeting.

Authors:  Xuan Zhou; Yi Zheng
Journal:  J Biol Chem       Date:  2013-11-07       Impact factor: 5.157

8.  Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro.

Authors:  Z Li; X Bi; M Wang; J Zhang; J Song; X Shen; J Han; G Fu; Y Ye
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

9.  Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.

Authors:  Claudia Mera; Iván Godoy; Renato Ramírez; Jackeline Moya; María Paz Ocaranza; Jorge E Jalil
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-10-21

10.  Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis.

Authors:  Francesca Cencetti; Caterina Bernacchioni; Paola Nincheri; Chiara Donati; Paola Bruni
Journal:  Mol Biol Cell       Date:  2010-01-20       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.